Effects of subthalamic nucleus stimulation and levodopa on decision-making in Parkinson's disease.


Journal

Movement disorders : official journal of the Movement Disorder Society
ISSN: 1531-8257
Titre abrégé: Mov Disord
Pays: United States
ID NLM: 8610688

Informations de publication

Date de publication:
03 2019
Historique:
received: 11 06 2018
revised: 26 10 2018
accepted: 30 11 2018
pubmed: 27 1 2019
medline: 21 12 2019
entrez: 26 1 2019
Statut: ppublish

Résumé

Parkinson's disease (PD) is frequently associated with behavioral disorders, particularly within the spectrum of motivated behaviors such as apathy or impulsivity. Both pharmacological and neurosurgical treatments have an impact on these impairments. However, there still is controversy as to whether subthalamic nucleus deep brain stimulation (STN-DBS) can cause or reduce impulsive behaviors. We aimed to identify the influence of functional surgery on decision-making processes in PD. We studied 13 PD patients and 13 healthy controls. The experimental task involved squeezing a dynamometer with variable force to obtain rewards of various values under four conditions: without treatment, with l-dopa or subthalamic stimulation alone, and with both l-dopa and subthalamic stimulation. Statistical analyses consisted of generalized linear mixed models including treatment condition, reward value, level of effort, and their interactions. We analyzed acceptance rate (the percentage of accepted trials), decision time, and force applied. Comparatively to controls, patients without treatment exhibited lower acceptance rate and force applied. Patients under l-dopa alone did not exhibit increased acceptance rate. With subthalamic stimulation, either with or without added l-dopa, all measures were improved so that patients' behaviors were undistinguishable from healthy controls'. Our study shows that l-dopa administration does not fully restore cost-benefit decision-making processes, whereas STN-DBS fully normalizes patients' behaviors. These findings suggest that dopamine is partly involved in cost-benefit valuation, and that STN-DBS can have a beneficial effect on motivated behaviors in PD and may improve certain forms of impulsive behaviors. © 2019 International Parkinson and Movement Disorder Society.

Sections du résumé

BACKGROUND
Parkinson's disease (PD) is frequently associated with behavioral disorders, particularly within the spectrum of motivated behaviors such as apathy or impulsivity. Both pharmacological and neurosurgical treatments have an impact on these impairments. However, there still is controversy as to whether subthalamic nucleus deep brain stimulation (STN-DBS) can cause or reduce impulsive behaviors.
OBJECTIVES
We aimed to identify the influence of functional surgery on decision-making processes in PD.
METHODS
We studied 13 PD patients and 13 healthy controls. The experimental task involved squeezing a dynamometer with variable force to obtain rewards of various values under four conditions: without treatment, with l-dopa or subthalamic stimulation alone, and with both l-dopa and subthalamic stimulation. Statistical analyses consisted of generalized linear mixed models including treatment condition, reward value, level of effort, and their interactions. We analyzed acceptance rate (the percentage of accepted trials), decision time, and force applied.
RESULTS
Comparatively to controls, patients without treatment exhibited lower acceptance rate and force applied. Patients under l-dopa alone did not exhibit increased acceptance rate. With subthalamic stimulation, either with or without added l-dopa, all measures were improved so that patients' behaviors were undistinguishable from healthy controls'.
CONCLUSIONS
Our study shows that l-dopa administration does not fully restore cost-benefit decision-making processes, whereas STN-DBS fully normalizes patients' behaviors. These findings suggest that dopamine is partly involved in cost-benefit valuation, and that STN-DBS can have a beneficial effect on motivated behaviors in PD and may improve certain forms of impulsive behaviors. © 2019 International Parkinson and Movement Disorder Society.

Identifiants

pubmed: 30681186
doi: 10.1002/mds.27625
doi:

Substances chimiques

Antiparkinson Agents 0
Levodopa 46627O600J

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

377-385

Subventions

Organisme : Agence Nationale de la Recherche
ID : ANR-09-MNPS-028-01
Pays : International
Organisme : PACA Regional Council and Orthomalin
Pays : International

Informations de copyright

© 2019 International Parkinson and Movement Disorder Society.

Auteurs

Cyril Atkinson-Clement (C)

Aix Marseille Université, CNRS, LPL, Aix-en-Provence, France.
Aix Marseille Université, CNRS, INT, Inst Neurosci Timone, Marseille, France.

Émilie Cavazzini (É)

Aix Marseille Université, CNRS, LPL, Aix-en-Provence, France.

Alexandre Zénon (A)

Institute of Neuroscience, Université Catholique de Louvain, Brussels, Belgium.
INCIA, Université de Bordeaux, CNRS UMR5287, Bordeaux, France.

Tatiana Witjas (T)

Aix Marseille Université, CNRS, INT, Inst Neurosci Timone, Marseille, France.
Aix Marseille Université, APHM, CHU Timone, Department of Neurology and Movement Disorders, Marseille, France.

Frédérique Fluchère (F)

Aix Marseille Université, APHM, CHU Timone, Department of Neurology and Movement Disorders, Marseille, France.
Aix Marseille Université, CNRS, LNC, Marseille, France.

Jean-Philippe Azulay (JP)

Aix Marseille Université, CNRS, INT, Inst Neurosci Timone, Marseille, France.
Aix Marseille Université, APHM, CHU Timone, Department of Neurology and Movement Disorders, Marseille, France.

Christelle Baunez (C)

Aix Marseille Université, CNRS, INT, Inst Neurosci Timone, Marseille, France.

Alexandre Eusebio (A)

Aix Marseille Université, CNRS, INT, Inst Neurosci Timone, Marseille, France.
Aix Marseille Université, APHM, CHU Timone, Department of Neurology and Movement Disorders, Marseille, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH